island Pharmaceutical Partners with Texas Biomed to Advance Galidesivir Growth for Marburg Virus
Table of Contents
Island Pharmaceutical Corp. has entered into a research agreement with Texas Biomedical Research Institute (Texas Biomed) to accelerate the development of galidesivir, its antiviral candidate for the treatment of Marburg virus. This collaboration leverages Texas Biomed’s specialized infrastructure and expertise in infectious disease research, particularly with high-containment pathogens, to support potential FDA approval through the Animal Rule pathway.https://www.islandpharmaceutical.com/news/island-pharmaceutical-corp-announces-research-agreement-with-texas-biomed-to-advance-galidesivir-development-for-marburg-virus/
Understanding the Threat: Marburg Virus and the Need for Countermeasures
Marburg virus is a highly virulent and lethal hemorrhagic fever virus. Like ebola, it causes severe bleeding, fever, and organ failure, with fatality rates ranging from 25% to 90% depending on the strain and quality of care. https://www.who.int/news-room/fact-sheets/detail/marburg-virus-disease Currently, there are no FDA-approved vaccines or therapeutics specifically for Marburg virus disease.The development of effective countermeasures is thus a critical public health priority.
Why Texas Biomed? A Unique Research Habitat
The partnership with Texas Biomed is strategically crucial due to the institute’s unique capabilities. These include:
* Biosafety Level 4 (BSL-4) Containment: Texas Biomed operates a BSL-4 facility, essential for safely studying highly perilous pathogens like Marburg virus. BSL-4 represents the highest level of biocontainment, requiring stringent safety protocols and specialized equipment to prevent the accidental release of the virus.
* Non-Human Primate (NHP) Resources: texas Biomed has extensive experience in non-human primate research, which is crucial for preclinical testing of antiviral therapies. NHPs provide a physiologically relevant model for studying marburg virus infection and evaluating the efficacy of galidesivir.
* Regulatory Expertise: The institute possesses deep expertise in navigating the regulatory requirements of the U.S. Food and Drug Governance (FDA), particularly concerning the development of medical countermeasures.
Texas biomed has a strong track record in infectious disease research, including prior studies involving lethal pathogens and hemorrhagic fever viruses. This experience is invaluable for efficiently generating data required for regulatory submissions.https://www.txbiomed.org/research/infectious-disease/
The Animal rule Pathway and Priority Review Voucher
The FDA’s Animal Rule pathway allows for the approval of medical products when human trials are not feasible or ethical. This is often the case for life-threatening diseases with limited patient populations, or when the pathogen poses an unacceptable risk to researchers. Approval under the Animal rule relies on robust preclinical data demonstrating efficacy in relevant animal models. https://www.fda.gov/regulatory-information/selected-fda-regulatory-approaches/animal-rule-fda-guidance
Moreover, a successful submission for a countermeasure against Marburg virus is eligible for a Priority Review Voucher. These vouchers can be redeemed to expedite the FDA review of another product, offering notable value to the pharmaceutical company.
Galidesivir is a broad-spectrum antiviral nucleotide prodrug. It works by inhibiting viral RNA polymerase, an enzyme essential for viral replication. Island Pharmaceutical is positioning galidesivir as a potential treatment for a range of viral infections, including Marburg. https://www.islandpharmaceutical.com/pipeline/
Next Steps and Future Outlook
Island Pharmaceutical anticipates receiving further feedback from the FDA in the new year regarding the proposed study design for preclinical studies at Texas Biomed. This feedback will inform the finalization of the clinical trial program. the company is also actively seeking additional research partners to support the broader development of galidesivir.
Dr. David Foster, Managing Director of Island Pharmaceutical, emphasized the strategic importance of this collaboration: “Texas Biomed’s world-class expertise provides us with an optimal potential partner to progress this antiviral candidate toward FDA approval…Its BSL-4 capabilities and access to a National Primate Research Centre have the potential to efficiently generate data to underpin approval under the Animal Rule pathway.”
Key Takeaways:
Keep reading